In this work, we aimed to describe, in a cohort of archival NSCLC samples, the EGFR expression and mutation status, as well as mutations in the KRAS gene and the methylation status of the potential epigenetic marker genes CDH1, CDKN2Ap16, RASSF1A, TERT, and WT1 to determine gender-specific differences. This evidence concerns the gene RASSF1 and non-small cell lung carcinoma.